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Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging viral infection causing coronavirus disease 
2019 (COVID-19). Hydroxychloroquine and chloroquine have garnered unprecedented attention as potential therapeutic agents 
against COVID-19 following several small clinical trials, uncontrolled case series, and public figure endorsements. While there is a 
growing body of scientific data, there is also concern for harm, particularly QTc prolongation and cardiac arrhythmias. Here, we per-
form a rapid narrative review and discuss the strengths and limitations of existing in vitro and clinical studies. We call for additional 
randomized controlled trial evidence prior to the widespread incorporation of hydroxychloroquine and chloroquine into national 
and international treatment guidelines.
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The first report of the novel coronavirus, SARS-CoV-2, causing 
coronavirus disease 2019 (COVID-19) originated in Wuhan, 
China, in early December 2019. Since then, the virus has spread 
across national borders, now affecting more than 200 countries 
and territories, with over 1 million confirmed cases and 56 000 
confirmed deaths as of April 4th, 2020 [1]. Accounts of limited 
personal protective equipment, lack of critical care resources 
such as ventilators, and healthcare worker shortages have be-
come unfortunate daily realities as researchers scramble to 
identify strategies to both interrupt transmission and treat the 
disease. To date, there are more than 300 ongoing clinical re-
search trials investigating potential therapeutic options for the 
prevention and/or treatment of COVID-19 [2].
Hydroxychloroquine and chloroquine have been labeled as 
potential “game-changers” in the popular press for COVID-19 
[3]. In this rapid review, we provide an overview of these medi-
cations, their pharmacology, the possible mechanisms of action 
against SARS-CoV-2, and appraise the body of evidence of in 
vitro and clinical studies that have been published to date. We 
discuss their strengths and limitations, and we call for additional 
large scale randomized clinical trials adequately powered to 
show a demonstrable impact on meaningful clinical outcomes, 
before national and international guidelines endorse the wide-
spread use of hydroxychloroquine/chloroquine for COVID-19.
PHARMACOLOGY OF HYDROXYCHLOROQUINE AND 
CHLOROQUINE
Chloroquine was first synthesized in 1934 and has been pre-
scribed extensively for the prevention and treatment of malaria 
as well as the treatment of autoimmune conditions, such as 
rheumatoid arthritis and systemic lupus erythematosus [4, 5]. 
Hydroxychloroquine was later introduced in 1955 and quickly 
became favored due to its superior safety profile [4]. The mech-
anism of action of these drugs against Plasmodium parasites is 
believed to be partly related to its interaction with DNA and 
through inhibition of the polymerization of heme [6, 7]. The 
immunomodulatory activity of hydroxychloroquine is related 
to a broad spectrum of immunoregulation networks discussed 
extensively in other work [5, 8, 9]. In addition to activity against 
rheumatic diseases, the two antimalarial agents have also shown 
therapeutic activity or immune modulatory effects in a wide 
range of other diseases including antiphospholipid syndrome, 
amebiasis, HIV/AIDS, and some cancers [10–13].
These medicines are manufactured in tablet form for oral 
administration as chloroquine phosphate 500  mg (equivalent 
to 300  mg chloroquine base) and hydroxychloroquine sulfate 
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200  mg (equivalent to 155  mg hydroxychloroquine base) ac-
tive drug per tablet, respectively. Dosage varies by treatment 
indication (Table 1 and Supplemental Table 1) [4, 6, 7, 14–19]. 
Doses as high as 2000  mg hydroxychloroquine and chloro-
quine have been used for the acute treatment of malaria. Both 
hydroxychloroquine and chloroquine are notable for their long 
terminal and elimination half-lives of 22 and 20–60  days re-
spectively [6, 20]. In the urine, hydroxychloroquine has been 
detectable up to three months from time of last dose [6]. 
Hydroxychloroquine has been shown to reach peak plasma 
concentration within three-four hours [6], whereas chloroquine 
can reach its peak plasma concentration in half an hour [20].
ADVERSE EVENTS
The most common adverse events of hydroxychloroquine 
and chloroquine are gastrointestinal upset along with nausea, 
vomiting, and diarrhea [14–16]. In a study evaluating the use 
of chloroquine, nearly 24% of patients reported nausea/abdom-
inal cramps and 17% diarrhea as side effects [17]. Up to 50% of 
patients receiving hydroxychloroquine report some gastrointes-
tinal effect; this appears to be dose-dependent and most often 
occurs with loading doses of 800 mg or higher [21]. Retinopathy 
is one of the most frequently observed, severe, and irreversible 
side effect associated with high-dose (>5  mg/kg) and long-
term use (>5 years) [19]. Chloroquine has a higher risk of ret-
inopathy than hydroxychloroquine [22]; however, this is not a 
concern with short term dosing [23]. The most severe and life-
threatening complications from use of hydroxychloroquine and 
chloroquine include QTc prolongation and the resultant risk of 
ventricular arrhythmias [4].
The incidence of QTc prolongation in this setting of chloro-
quine and hydroxychloroquine use is largely unknown, as it is 
highly dependent on baseline EKG findings, with risk exacer-
bated by the use of concomitant QTc-prolonging medications. 
In a study of healthy participants, 600 mg chloroquine was asso-
ciated with an average QTc increase of 16ms (95% CI: 9-23ms), 
while 1500 mg chloroquine was associated with a 28ms increase 
(95% CI: 18-38ms), with the most significant QTc prolon-
gation four hours after the second dose [24]. Studies related 
hydroxychloroquine and QTc prolongation are largely limited 
to case reports of chronic use [25, 26]. EKG monitoring is not 
part of standard practice for malaria treatment nor for rheuma-
tology use, when used as monotherapy.
Significant drug interactions with chloroquine and 
hydroxychloroquine that should be avoided or require addi-
tional monitoring include digoxin, antiepileptics, antacids, cy-
closporine, amiodarone, azithromycin, moxifloxacin, insulin 
and antidiabetic agents, tamoxifen, and praziquantel [27–28]. 
The combination of azithromycin with hydroxychloroquine 
frequently prolongs the QTc interval in a clinically significant 
manner, increasing over time. In an 84 patient consecutive 
cohort, 18% of patients’ QTc increased by 40–60 ms, and 12% 
increased by >60 ms with 11% overall having QTc >500 ms [29]. 
Other adverse effects from acute use of hydroxychloroquine 
and chloroquine include, but are not limited to: hypoglycemia 
in diabetic patients; neurotoxicity in the form of tinnitus, head-
aches, and changes in mood; and hemolytic anemia in those 
with G6PD deficiency [6, 27].
HYDROXYCHLOROQUINE, CHLOROQUINE, AND 
SARS-COV-2
The mechanism of action of hydroxychloroquine/chloroquine 
against SARS-CoV-2 has yet to be fully elucidated. Chloroquine 
was first studied in SARS-CoV [30], which was responsible for 
the 2002–2003 SARS coronavirus epidemic. SARS-CoV shares 
79% genetic sequence similarity to SARS-CoV-2, but is thought 
to result in more severe infection with a case fatality rate of 10% 
vs. 3% for SARS-CoV-2 [31, 32]. Based on studies initially per-
formed on SARS-CoV, it is believed that SARS-CoV-2 enters 
cells by binding to the angiotensin-converting enzyme 2 (ACE-
2) receptor, and that chloroquine may prevent the virus from 
binding to this receptor by inhibiting terminal glycosylation 
[30]. New research has proposed that hydroxychloroquine may 
additionally prevent SARS-CoV-2 from binding with ganglio-
sides, which in turn may inhibit virion contact with the ACE-2 
receptor [33]. Both hydroxychloroquine and chloroquine ad-
ditionally can incorporate into endosomes and lysosomes, 
resulting in an increased pH of intracellular compartments. 
These organelles normally require an acidic environment for 
homeostasis. Ultimately, this increase in pH results in their 
dysfunction, leading to defective protein degradation, endocy-
tosis, and exocytosis needed for viral infection, replication, and 
propagation [34]. Prior work has also demonstrated that cor-
onaviruses can use proteins on the surface of endosomes and 
endolysosomes for viral entry into host cells [35]. Entry into 
the endolysosome may be necessary for the viral genome to be 
released into the cytoplasm of infected host cells [36]. However, 
it remains unclear how changes in the endosomal environment, 
particularly changes in pH, may affect the integrity of the SARS-
CoV-2 viral genome. Overall, hydroxychloroquine/chloroquine 
are capable of affecting several cellular pathways and therefore 
may have several mechanisms of action against SARS-CoV-2.
HYDROXYCHLOROQUINE, CHLOROQUINE, AND 
SARS-COV-2 IN VITRO DATA
Prior to the 2019 SARS-CoV-2 pandemic, in vitro studies in-
vestigated the ability of chloroquine to inhibit SARS-CoV viral 
replication. In these studies, researchers discovered that by 
pretreating cells with chloroquine at a concentration of 10μM, 
chloroquine inhibited SARS-CoV viral replication as deter-
mined by indirect immunofluorescence [30]. When tested as a 
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dose (ED50) of chloroquine was determined to be 4.4  ±  1µM 
[30]. Another study demonstrated that a chloroquine concen-
tration of 8.8 ± 1.2µM could inhibit viral replication by 50%, 
though the exact infectious viral dose used in this study was 
unclear [37]. In 2006, Biot et al. demonstrated that chloroquine 
was more potent than hydroxychloroquine in vitro at inhibiting 
SARS-CoV replication in a Vero cell model (EC50 6.5 ± 3.2µM 
vs 34 ± 5µM, respectively) [38].
Since the current 2019 outbreak, researchers have built 
upon this knowledge to assess whether or not chloroquine 
may inhibit SARS-CoV-2. Earlier this March, Yao et  al. pub-
lished results of an antiviral assay using SARS-CoV-2 in-
fected Vero cell lines. In contrast to the above findings with 
SARS-CoV, hydroxychloroquine was found to be more po-
tent against SARS-CoV-2 [39]. This experiment demonstrated 
that hydroxychloroquine was more effective at impairing 
viral replication compared to chloroquine when given post-
infection, with a 48-hour EC50 of 0.72µM and 5.47µM for 
hydroxychloroquine and chloroquine respectively [39]. 
Moreover, hydroxychloroquine was more effective than chloro-
quine at impairing SARS-CoV-2 viral replication when given 
prophylactically; the 48-hour EC50 for hydroxychloroquine 
and chloroquine were 5.85µM and 18.01µM respectively [39]. 
Additional work focused solely on chloroquine denoted similar 
in vitro antiviral findings [40, 41].
To identify a potential drug regimen for use in humans, 
physiologically based pharmacokinetic modeling was em-
ployed by Yao et  al. to consider drug administration route, 
physiological parameters (i.e., intestinal absorption and lung 
tissue penetration), and drug biochemical properties. The 
publication reported simulated lung fluid concentrations 
but did not provide all the details used in the model [39]. 
The most promising regimen for the treatment of COVID-
19 based on this modeling was an initial dose of 400  mg 
hydroxychloroquine twice daily and a maintenance dose of 
200 mg twice daily for four days [39]. A 95% confidence in-
terval for the estimate of the EC50 was not provided, and thus 
this dosing regimen should be interpreted with caution as it 
may be an inaccurate estimate.
Using a similar antiviral assay at four different multiplicities 
of infection as previously described, Liu et  al. demonstrated 
that chloroquine was more potent than hydroxychloroquine 
at impairing viral replication at all multiplicities of infection 
tested. However, the effect was only statistically significant at 
multiplicities of infection of 0.01 and 0.2 [42]. To assess SARS-
CoV-2 specific virion entry into the endosome lysosome 
degradation pathway, Liu et  al. used a colocalization immu-
nofluorescence assay. They determined that cells treated with 
hydroxychloroquine or chloroquine had significantly more vi-
rion localized to the early endosomes and fewer localized to 
endolysosomes when compared to untreated viral infected cells 
[42]. Together, these findings suggest that hydroxychloroquine 
and chloroquine are effective at impairing SARs-CoV-2 repli-
cation in vitro.
EVIDENCE FOR HYDROXYCHLOROQUINE AND 
CHLOROQUINE USE IN THE TREATMENT OF 
COVID-19
As of April 6, 2020, the published evidence of the effective-
ness of hydroxychloroquine or chloroquine for the preven-
tion and treatment of COVID-19 in humans is limited to five 
small studies and one subjective report (Table  2) [43–48]. 
In early March, Chen et  al. published the results of the first 
hydroxychloroquine study in patients with COVID-19 [43]. 
In this small, 30-person inpatient, randomized controlled trial 
comparing hydroxychloroquine to the standard of care, re-
searchers found no statistically significant differences in time 
to viral clearance by day seven between those who received 
hydroxychloroquine (87% clearance) versus those who did not 
(93%, P > .05). They also did not identify any difference in clin-
ical outcomes (i.e., duration of fever, changes in lung imaging). 
While they did not comment on the severity of illness of those 
enrolled, those in the hydroxychloroquine and control arms 
had symptoms for approximately seven and six days respec-
tively. At two weeks, all patients had negative viral nucleic acid 
tests. On March 16, 2020, Gao et al., extracted data from 100 
patients with confirmed COVID-19 from ongoing inpatient 
studies in China and reported patient improvement with the 
use of chloroquine [48]. The authors claimed that chloroquine 
was superior to standard of care treatment in helping reduce 
time to clinical recovery and improving lung imaging findings; 
however, no data supporting these findings were published, and 
no clinical information, including the severity of illness and 
outcomes, nor statistical analyses were presented in this brief 
report [48].
On March 20, 2020, Gautret et al. reported results from a non-
randomized, open-label study in France, with absent blinding, 
assessing hydroxychloroquine compared to standard of care 
treatment, garnering much attention [44]. Twenty-six hospital-
ized patients were treated with hydroxychloroquine (600 mg for 
ten days), six of whom received azithromycin (500 mg, followed 
by 250  mg for a total of five days). Sixteen patients who did 
not meet study inclusion criteria served as study controls. At 
the time of enrollment, nearly 17% of all patients were asymp-
tomatic, 61% had upper respiratory symptoms, and 22% had 
pneumonia or bronchitis-like symptoms. In unadjusted ana-
lyses, the authors found significantly reduced viral titers in those 
who received hydroxychloroquine at day six compared to those 
who did not (70% vs. 12.5%, P < .001); however, six participants 
in the hydroxychloroquine treatment arm (23%) were excluded 
from analysis as they required intensive care admission, died, 
withdrew from the study, or were lost to follow-up. Given the 
small sample size of the overall study and the exclusion of these 
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the results are significantly biased, and no definitive conclusion 
should be drawn. Long term outcome data from this study were 
not available, and the reported outcome of viral clearance may 
not be a good surrogate for important patient-centered out-
comes, such as the need for mechanical ventilation, or mor-
tality. Of the six patients who received azithromycin in addition 
to hydroxychloroquine, all patients had a negative SARS-CoV-2 
PCR test by day 6 without comparison to adequate controls.
Gautret et  al. also recently released results of another 
open-label unblinded study, assessing the combination of 
hydroxychloroquine and azithromycin in 80 hospitalized pa-
tients using the same dosing regimen as previously described 
[44, 47]. Six patients included in this analysis were included in 
the original study. Nearly 58% of these patients had at least one 
underlying chronic health condition. Four patients were asymp-
tomatic at baseline, whereas 41% had upper respiratory tract 
symptoms, and 54% had pneumonia or bronchitis-like symp-
toms. Approximately 92% of patients had a low national early 
warning score, indicating that the overall severity of illness in 
this population was mild. They reported 83% of patients having 
undetectable nasopharyngeal viral loads on day seven; however, 
there was no comparison group and thus, the results are nearly 
impossible to interpret. In this study, 81% (65/80) of patients 
survived to hospital discharge, whereas three patients required 
intensive care, one died, and eleven were still hospitalized.
On March 31, 2020, Chen et al. published results of a ran-
domized parallel-group trial, where 62 hospitalized participants 
were randomized to receive either 400mg hydroxychloroquine 
for five days in addition to standard of care or standard of care 
alone [45]. No placebo was utilized in this study. Standard 
of care was defined as oxygen, antiviral agents, antibacterial 
agents, and immunoglobulin, with or without corticosteroids. 
Only patients with chest CT confirmed pneumonia and mild 
illness with SaO2/SpO2 >93% or PaO2/FiO2 > 300 mmHg were 
allowed to enroll. While the researchers found a more sub-
stantial proportion of those receiving hydroxychloroquine had 
clinical improvement of pneumonia (80% vs. 55%, P < .04) as 
determined by day zero to day six chest CT, the methodology 
was not described. Outcomes were likely based on subjective 
individual clinician opinion, which may not have been blinded 
to the treatment allocation. Decreased duration of cough (2.0 
vs. 3.1 days, P < .001), and shortened time to clinical recovery 
were also reported for those receiving hydroxychloroquine 
when compared to the controls; however, only 48% (15/31) of 
those randomized to hydroxychloroquine and 71% (22/31) of 
controls had cough at baseline and it is unknown for what du-
ration. Four patients in the control group were said to have pro-
gressed to severe illness, though severe illness was not defined. 
No underlying patient comorbidities were examined, and this 
may have been an overall confounding variable. Additionally, 
the specific antiviral and antibacterial medications utilized as 
a part of standard of care treatment were unspecified and may 
have affected the results. Overall, similar to prior studies, se-
rious limitations exist, and the results of this non-peer reviewed 
study should be interpreted with appropriate caution.
On April 3rd, Molina et  al. reported outcomes of a pro-
spective cohort of 11 hospitalized patients in response to 
Gautret et al.’s work [46]. These patients all received the same 
dose and duration of hydroxychloroquine and azithromycin 
as the Gautret study. Eight patients enrolled had significant 
comorbidities, and at the time of enrollment, 10/11 were re-
ceiving oxygen supplementation. They found that 80% (95% CI: 
49–94%) of patients alive by days five-six still had SARS-CoV-2 
RNA positive nasopharyngeal swabs, in contrast to other find-
ings that suggested reduced viral titers. In this small cohort, two 
patients were transferred to intensive care, one patient died, 
and one had the medications stopped due to QTc prolongation. 
Unlike the Gautret study, these sicker patients were included in 
the analysis.
Importantly, all six of these studies have several important 
limitations that preclude their incorporation into clinical guide-
lines. All studies had small sample sizes (<100 participants) and 
were underpowered to demonstrate a clinical or statistical dif-
ference in outcomes. Only two studies were randomized con-
trolled trials, while two were a non-randomized non-blinded 
open-label study, one was a prospective cohort, and one in-
cluded a combination of patients from ongoing clinical trials 
without any statistical assessment available. Four of the five 
hydroxychloroquine studies shared the same dosing regimen 
(400  mg hydroxychloroquine for five days); but based on in 
vitro data, doses as high as 800 mg, if not higher, followed by 
400 mg for several days, may be required for effective viral clear-
ance in humans [39]. Only one of the six studies was officially 
peer-reviewed, though concerns have been raised about this 
article [49]. These studies should, therefore, be interpreted as 
solely hypothesis-generating and should not serve as supporting 
evidence for the widespread inclusion of hydroxychloroquine/
chloroquine in clinical guidelines. Given that all of these studies 
reported differences in the disease severity, the overall patient 
populations may not be comparable. Moving forward, re-
searchers should report the severity of COVID-19 illness based 
on symptom duration as well as using a systematic, severity scale.
Despite this dearth of evidence of efficacy, in light of the 
pressure that COVID-19 has posed on national health sys-
tems, several official guidelines have already incorporated 
hydroxychloroquine and chloroquine into the suggested treat-
ment of patients with COVID-19 [28, 50, 51]. A  subsequent 
surge in prescriptions has caused widespread shortages of 
hydroxychloroquine, which has threatened the supply of this 
medication for patients with autoimmune diseases like systemic 
lupus erythematosus and rheumatoid arthritis. The incorpora-
tion of these medications into national treatment guidelines has 
several consequences. While hydroxychloroquine and chloro-






/ofid/article-abstract/7/4/ofaa130/5820538 by guest on 08 M
ay 2020
Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19) • ofid • 7
there are important side effects. Although side effects are not 
common with these medicines, rare adverse effects of a medica-
tion that is prescribed commonly without a rigorous evidence 
base can be dangerous on a population level. Bluntly stated, any 
significant side effect is not justifiable if the drug is not effective. 
Given these potentially deleterious consequences of widespread 
use of these drugs in the absence of robust data, the European 
Medicines Agency has refused to approve chloroquine for 
COVID-19 and has restricted its use to solely clinical trials or 
through national emergency use programs [52].
To date, there are no studies of hydroxychloroquine as treat-
ment of COVID-19 that are adequately powered to demonstrate 
efficacy or the absence of harm. Presently over 1 million cases 
of COVID-19 have been identified. If all patients had received 
hydroxychloroquine or chloroquine, even if, for example, QTc 
prolongation and arrhythmia are seen in less than 0.1% of the 
population, this would equate to 1000 adverse events, which is 
arguably not acceptable if the medication is not effective. Of 
note, Gautret and Molina examined the treatment of COVID-
19 with combination hydroxychloroquine and azithromycin, 
which many clinicians have now started to prescribe together, 
without evidence, in the outpatient setting. In these studies, 
this combination was utilized in an inpatient environment, 
presumably with some degree of cardiac monitoring. Both 
azithromycin and hydroxychloroquine, alone, but especially 
in combination, can increase the risk of QTc prolongation, and 
lead to malignant arrhythmias [4, 6]. In a retrospective pop-
ulation study of 60 000 patients receiving hydroxychloroquine 
for rheumatic disease, researchers found an increased risk of 
cardiovascular mortality when hydroxychloroquine was used 
in combination with azithromycin (50 deaths) when compared 
to hydroxychloroquine and amoxicillin (25 deaths) (Hazard 
Ratio: 2.19, 95% CI: 1.22–3.94); however, all-cause mortality 
was the same (Hazard Ratio 1.34) [53]. This risk can be signifi-
cantly increased when considering other commonly prescribed 
medications with the potential for QTc prolongation like se-
lective serotonin reuptake inhibitors, tricyclic antidepressants, 
antipsychotics, and various antimicrobials. These small studies 
demonstrate insufficient evidence to therefore support the rou-
tine use of hydroxychloroquine and azithromycin outside of a 
clinical trial with adequate cardiac monitoring.
As a final consideration, lopinavir/ritonavir, a protease inhib-
itor broadly available for treating HIV infection with in vitro 
activity against SARS-CoV infection, has been recommended 
by the Chinese authorities to treat COVID-19. A recent open-
label randomized trial of 14 days of lopinavir/ritonavir therapy 
among severely ill patients hospitalized with COVID-19 showed 
no clinical improvement and no reduction in SARS-CoV-2 viral 
load beyond standard care [54]. Despite these negative results, 
lopinavir/ritonavir is still commonly used to treat COVID in 
some settings, often concomitantly with hydroxychloroquine 
or chloroquine. Importantly, lopinavir/ritonavir can potentially 
increase chloroquine plasma levels by inhibition of cytochrome 
P450 CYP2D6 enzyme metabolism, therefore increasing the 
risk for malignant arrhythmias. Moreover, other factors such as 
myocarditis and myocardial ischemia, reported in the context of 
COVID-19 [55], or hypoxia and electrolyte abnormalities, often 
seen in the acute phase of severe COVID-19, can further con-
tribute to the development of acute arrhythmias [56]. Thus, this 
calls for prudent and well-informed use of lopinavir/ritonavir 
and QTc-prolonging medications, like hydroxychloroquine and 
azithromycin, to treat COVID-19.
CONCLUSION
Additional studies examining hydroxychloroquine and chlo-
roquine in preventing and treating COVID-19 are des-
perately needed. Given the weak evidence available, larger 
controlled trials are needed to more thoroughly assess if 
hydroxychloroquine/chloroquine have a clinical benefit in 
COVID-19. Several ongoing randomized clinical trials are ac-
tively recruiting participants to better address this question. 
These randomized trials are powered to show a reduction in 
meaningful clinical outcomes such as the development of 
COVID-19 in prevention trials or the need for hospitalization, 
critical care, or death in treatment trials. The results of these 
trials will be instrumental in determining whether or not these 
two antimalarial medications are at all efficacious, and if so, at 
what dose and for what duration they should be safely recom-
mended in guidelines.
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